Robot-Assisted Radical Cystectomy: A Complete Audit Cycle of Our First 120 Cases
BAUS ePoster online library. Eli N. 06/22/21; 319006; p10-17
Disclosure(s): None
Mr. Nnaemeka Eli
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
There are 10,200 new cases of bladder cancer diagnosed every year in the UK accounting for 3% of all new cancer diagnoses. Robot-assisted radical cystectomy (RARC) is a minimal invasive treatment option for muscle invasive and high risk bladder cancer with a rising uptake. Between 2017 and 2019, RARC accounted for 40.7% of all cystectomies performed in the UK.
We compared our outcomes with the best practice of RARC set by the Pasadena consensus panel in 2015.
Materials and Methods
A review of the prospectively maintained database of all RARC performed in our Centre by two surgeons between May 2013 and October 2020 was conducted. Operative and oncological outcome data were collected from Clinical Web Portal and Somerset cancer Register and analysed using Microsoft Excel.
Results
A total of 120 RARC were performed in the study period, 50 cases were analysed in the first audit loop and 70 cases in the second loop. The mean age was 69 years (44 – 82), 84% were men and 70% were ASA grade 2 or less. The median operating time was 378 minutes and the median blood loss was 250mls. 80% of the urinary diversion was intra-corporeal and 85% was Ileal conduit diversion. The median length of stay was 8 days; complication rate with Clavien Dindo score of III or higher was 12.5%. 87% of our patients are still alive.
Conclusion
RARC is a safe option for the radical management of bladder cancer. Our outcomes are consistent with the Pasadena consensus recommendations.
There are 10,200 new cases of bladder cancer diagnosed every year in the UK accounting for 3% of all new cancer diagnoses. Robot-assisted radical cystectomy (RARC) is a minimal invasive treatment option for muscle invasive and high risk bladder cancer with a rising uptake. Between 2017 and 2019, RARC accounted for 40.7% of all cystectomies performed in the UK.
We compared our outcomes with the best practice of RARC set by the Pasadena consensus panel in 2015.
Materials and Methods
A review of the prospectively maintained database of all RARC performed in our Centre by two surgeons between May 2013 and October 2020 was conducted. Operative and oncological outcome data were collected from Clinical Web Portal and Somerset cancer Register and analysed using Microsoft Excel.
Results
A total of 120 RARC were performed in the study period, 50 cases were analysed in the first audit loop and 70 cases in the second loop. The mean age was 69 years (44 – 82), 84% were men and 70% were ASA grade 2 or less. The median operating time was 378 minutes and the median blood loss was 250mls. 80% of the urinary diversion was intra-corporeal and 85% was Ileal conduit diversion. The median length of stay was 8 days; complication rate with Clavien Dindo score of III or higher was 12.5%. 87% of our patients are still alive.
Conclusion
RARC is a safe option for the radical management of bladder cancer. Our outcomes are consistent with the Pasadena consensus recommendations.
Introduction
There are 10,200 new cases of bladder cancer diagnosed every year in the UK accounting for 3% of all new cancer diagnoses. Robot-assisted radical cystectomy (RARC) is a minimal invasive treatment option for muscle invasive and high risk bladder cancer with a rising uptake. Between 2017 and 2019, RARC accounted for 40.7% of all cystectomies performed in the UK.
We compared our outcomes with the best practice of RARC set by the Pasadena consensus panel in 2015.
Materials and Methods
A review of the prospectively maintained database of all RARC performed in our Centre by two surgeons between May 2013 and October 2020 was conducted. Operative and oncological outcome data were collected from Clinical Web Portal and Somerset cancer Register and analysed using Microsoft Excel.
Results
A total of 120 RARC were performed in the study period, 50 cases were analysed in the first audit loop and 70 cases in the second loop. The mean age was 69 years (44 – 82), 84% were men and 70% were ASA grade 2 or less. The median operating time was 378 minutes and the median blood loss was 250mls. 80% of the urinary diversion was intra-corporeal and 85% was Ileal conduit diversion. The median length of stay was 8 days; complication rate with Clavien Dindo score of III or higher was 12.5%. 87% of our patients are still alive.
Conclusion
RARC is a safe option for the radical management of bladder cancer. Our outcomes are consistent with the Pasadena consensus recommendations.
There are 10,200 new cases of bladder cancer diagnosed every year in the UK accounting for 3% of all new cancer diagnoses. Robot-assisted radical cystectomy (RARC) is a minimal invasive treatment option for muscle invasive and high risk bladder cancer with a rising uptake. Between 2017 and 2019, RARC accounted for 40.7% of all cystectomies performed in the UK.
We compared our outcomes with the best practice of RARC set by the Pasadena consensus panel in 2015.
Materials and Methods
A review of the prospectively maintained database of all RARC performed in our Centre by two surgeons between May 2013 and October 2020 was conducted. Operative and oncological outcome data were collected from Clinical Web Portal and Somerset cancer Register and analysed using Microsoft Excel.
Results
A total of 120 RARC were performed in the study period, 50 cases were analysed in the first audit loop and 70 cases in the second loop. The mean age was 69 years (44 – 82), 84% were men and 70% were ASA grade 2 or less. The median operating time was 378 minutes and the median blood loss was 250mls. 80% of the urinary diversion was intra-corporeal and 85% was Ileal conduit diversion. The median length of stay was 8 days; complication rate with Clavien Dindo score of III or higher was 12.5%. 87% of our patients are still alive.
Conclusion
RARC is a safe option for the radical management of bladder cancer. Our outcomes are consistent with the Pasadena consensus recommendations.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}